OVERVIEW
The Global Aptamers Market is calculated to reach USD 416.69 million by 2024. It is expected to grow at a CAGR of 18.12% during the forecast period 2019-2024. The major drivers for the market include a strong trend of R&D investments in biotechnology and pharmaceutical industries, patent expiration of systematic evolution of ligands by exponential enrichment technology (SELEX), technological advancements, and the low cost and high efficiency of aptamers in binding to large molecules as compared to antibodies.
TABLE OF CONTENT
1 Global Aptamers Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope
2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions
3 Global Aptamers Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography
4 Global Aptamers Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis
5 Global Aptamers Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies
6 Global Aptamers Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.1.1 High advantage of aptamers compared to antibodies
6.2.1.2 Advancements in the field of aptamer development technologies
6.2.1.3 Growing investment by major companies
6.2.2 Restraints
6.2.2.1 Increasing number of setbacks of aptamer therapeutics in late stage clinical studies
6.2.2.2 Low awareness level and incomplete regulatory policies
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes
7 Global Aptamers Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Product Life Cycle
7.3 Supplier and distributor analysis (Market share and product dealing strategies)
8 Global Aptamers Market – By Type (Market Size – & million/billion)
8.1 Nucleic Acid Aptamers
8.2 Peptide Aptamers
9 Global Aptamers Market – By Application
9.1 Diagnostics
9.2 Therapeutics
9.3 R&D
9.4 Others
10 Global Aptamers Market – By End-User
10.1 Academic & Government Research Institutes
10.2 Biotechnology & Pharmaceutical Companies
10.3 Contract Research Organizations
10.4 Other
11 Global Aptamers Market – By Geography (Market Size – & million/billion)
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 U.K
11.3.2 Germany
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia-Pacific
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 South Korea
11.4.5 Rest of APAC
11.5 Rest of the World
11.5.1 South America
11.5.2 Middle East
11.5.3 Africa
12 Global Aptamers Market – Entropy
12.1 New product launches
12.2 M&A’s, collaborations, JVs and partnerships
13 Global Aptamers Market Company Profile (Key Players)
13.1 Market Share, Company Revenue, Products, M&A, Developments
13.2 Base Pair Biotechnologies, Inc.
13.3 TriLink BioTechnologies, Inc.
13.4 Aptagen, LLC
13.5 AM Biotechnologies, LLC
13.6 Aptamer Sciences, Inc.
13.7 NOXXON Pharma
13.8 SomaLogic Inc.
13.9 Aptamer Group
13.10 Aptus Biotech S.L.
13.11 Vivonics, Inc.
13.12 Company 11 & more
14 Global Aptamers Market – Appendix
14.1 Sources
14.2 Abbreviations
